Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It improves the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
IPO Year: 2015
Exchange: NASDAQ
Website: zynerba.com
| Date | Price Target | Rating | Analyst |
|---|
15-12G - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
EFFECT - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
POS AM - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
S-8 POS - Zynerba Pharmaceuticals, Inc. (0001621443) (Filer)
DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne Hanlon who will retire from her position at the end of February 2022. "We are excited to have Al join our senior leadership team. He is an experienced legal and business executive who brings significant strategic and hands-o
EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced the recent appointments of Richard Baron to Immunome’s Board of Directors and as Audit Committee Chair, and Sandra Stoneman, Esq. as Chief Legal Officer and Corporate Secretary. The company also today announced that its President and Chief Executive Officer, Purnanand Sarma, Ph.D. is the recipient of TiE Boston’s 2020 Lifetime Achievement Award. The award recognizes individuals who have made invaluab
New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders with high unmet medical needs Zygel™ in pivotal Phase 3 trial for Fragile X syndrome and has completed Phase 2 proof-of-concept study in 22q11.2 deletion syndrome PLYMOUTH MEETING, Pa., Oct. 11, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE).
PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ:ZYNE), a leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, including Fragile X syndrome (FXS). Under the terms of the definitive agreement, Harmony
– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments – – Safety data reinforce excellent tolerability profile of Zygel – – Company will focus resources on FXS and 22q development – – Cash runway extended through the end of 2023 / early 2024 – – Zynerba to host conference call and webcast tomorrow, June 22, 2022 at 9:00 a.m. ET – DEVON, Pa., June 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced positive top line results from the explorat
– Company plans to focus development of Zygel™ in FXS, ASD and 22q – – Company plans to initiate Phase 3 trial with Zygel in ASD in the second half of 2022 – – Zynerba to hold conference call tomorrow, January 5, 2022 at 9:00 a.m. ET – DEVON, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q) and developmental and epileptic encephalopathies (DEE). In addition to the continued clinical development o